A framework for deciding between spinning out a NewCo and selling down an asset.
Cross-border life-science transactions reward teams that combine scientific judgement with disciplined deal execution. The most durable outcomes come from aligning incentives early and structuring for the relationship that has to survive long after signatures.
Our view is shaped by mandates run end to end – from first asset screen through diligence, negotiation, and integration across global pharma and biotech.